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PEMBANGUAN SISTEM PENYAMPAIAN BAHARU 
BERASASKAN EXOSOME BAGI PROTEIN  
ABSTRAK 
 
Sel mempunyai beribu-ribu protein yang menyumbang kepada laluan isyarat penting 
terhadap fungsi sel normal. Kebanyakan penyakit terjadi akibat daripada kepincangan tugas 
salah satu atau lebih daripada protein berkenaan. Untuk meredakan disfungsi berkenaan, 
terapi protein yang menggunakan protein terapeutik untuk membetulkan fungsi sel dianggap 
pendekatan yang paling selamat untuk merawat penyakit. Terdapat lebih daripada 1,500 
sasaran rawatan penyakit yang berpotensi di dalam sel tanpa laluan reseptor yang jelas 
sebagai sasaran khusus mereka. Keperluan untuk penghantaran intra sel yang mensasarkan 
sel perumah tertentu merupakan satu halangan yang sukar dalam pembangunan intra sel 
baharu yang berasaskan protein. Exosomes yang bersaiz 40-120nm, merupakan vesikel 
membran yang dirembeskan oleh sel dan telah dikenalpasti sebagai pengangkutan semulajadi 
untuk penghantaran makromolekul. Exosomes berinteraksi dengan sel dan turut memberi 
kesan terhadap fungsi sel lain yang berdekatan melalui pemindahan inter sel mRNA, 
microRNA, reseptor dan enzim, dan didapati memainkan peranan penting dalam kawalselia 
imun. Beberapa protein virus seperti protein HIV-1 Nef, Vif dan VSV-G dilaporkan 
meransang pengeluaran exosome. Pemerhatian ini membawa kepada hipotesis bahawa 
expresi berlebihan yang serentak daripada protein perangsang exosome/ exosome inducing 
protein (ExIP) dan protein heterologous dari vektor plasmid yang sama akan menyebabkan 
pengeluaran exosome yang mengandungi protein yang dikehendaki. Untuk menguji hipotesis 
ini, kami telah membangunkan vektor mamalia bicistronic dalam expresi pelbagai ExIP dan 
GFP secara serentak sebagai protein reporter. Kami telah mendapati bahawa kedua-dua 
protein HIV-1 Nef dan VSV-G berupaya meransang induksi exosome yang mengandungi 
GFP. Pemerhatian ini berupaya membawa kepada kemungkinan baharu untuk penghantaran 
xv 
 
protein rekombinan (seperti antibodi) secara cekap dan merintis jalan baharu dari segi 
pembangunan ubat biologi berasaskan protein intra sel. 
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DEVELOPMENT OF NOVEL EXOSOME-BASED DELIVERY 
SYSTEM FOR PROTEINS 
ABSTRACT 
 
A cell contains thousands of proteins that contribute to critical signalling pathways 
in normal cellular functions. Most diseases somehow result from the malfunction of one or 
more of such proteins. To palliate such dysfunction, protein therapy that makes use of 
therapeutic proteins to correct the cellular functions is considered the most direct and safe 
approach for treating diseases. There are more than 1,500 potential disease treatment targets 
that reside inside the cell, without a clear receptor pathway for their specific targeting. The 
need for intracellular delivery and targeting select host cell compartment represents a 
formidable hurdle to the development of novel prospective intracellular targeting protein-
based biologics. Exosomes, 40-120 nm membrane vesicles secreted by cells, have recently 
emerged as promising natural vehicles for the delivery of macromolecules. Exosomes 
interact with cells and affect the functions of neighbouring cells through intercellular transfer 
of mRNA, microRNA, receptors and enzymes, and found to play important roles in immune 
dysregulation. A number of viral proteins such as HIV-1 Nef, Vif and VSV-G protein are 
reported to induce exosome production. These observations lead us to hypothesize that 
simultaneous overexpression of exosome inducing proteins (ExIP) and a heterologous 
protein from the same plasmid vector will result in the production of exosomes that contain 
the desired protein. To test our hypothesis we have constructed bicistronic mammalian 
expression vectors that concomitantly express various ExIPs and GFP as a reporter protein. 
We have found that both HIV-1 Nef and VSV-G proteins induce the induction of GFP-
containing exosomes. These observations may lead to novel possibilities for the efficient 
delivery of recombinant proteins (such as antibodies) and opens up new avenues in terms of 
the development of intracellular protein biologic drugs. 
1 
 
CHAPTER 1.  INTRODUCTION 
1.1. Background 
The word “Protein” was proposed by Jöns Jakob Berzelius in 1838. He claimed that 
substances such as egg white, blood serum albumin, fibrin and wheat gluten are a 
combination of simple ratios of sulphur and phosphorus that are found in nature. He called 
these substances as “protein”. The word “protein” was coined from the Greek word π ρ ω τ ε 
ι˜ ο ς  (Vickery, 1950).  In general, a protein has a 3D structure formed from a long chain of 
amino acids and is involved in major functions within living organisms, including 
metabolism, DNA replication, response to stimuli, and movement. Some of the common 
diseases are a result of the failure of one or more proteins. To palliate such dysfunction, 
compensatory therapy using therapeutic proteins to correct the cellular functions is 
considered the most direct approach for treating such diseases (Dimitrov, 2012; Carter, 2011; 
Yan et al., 2010).  
Since the early 1980s, therapeutic proteins have been proposed as candidate therapy. 
Advances in protein engineering allow for the systemic dissection of protein structure-
function relationship, and the subsequent generation of novel proteins with enhanced 
activities or entirely new properties. Human insulin (Humulin
®
), the first human  therapeutic 
protein commercialized in 1982, is derived from recombinant DNA technology (Goeddel et 
al., 1979).      
Therapeutic proteins are divided into five major groups based on their designated 
pharmacological activities: (a) replacing a protein that is deficient or abnormal; (b) 
supplementing an existing pathway; (c) providing a novel function or activity; (d) interfering 
with a molecule or organism; and (e) delivering other compounds or proteins such as 
radionuclide, cytotoxic drug or effectors proteins (Dimitrov 2012). Therapeutic proteins 
include antibody-based drugs, anticoagulants, blood factors, bone morphogenetic proteins, 
engineered protein scaffolds, enzymes, Fc fusion proteins, growth factors, hormones, 
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interferon, interleukins and thrombolytics. To date, hundreds of therapeutic proteins are in 
various phases of clinical trials for cancer therapy, immune disorders, infection, and other 
illnesses. For example, Belimumab for systemic lupus erthematosus by Benlysta et al.,  2011;  
Ipilimumab for metastatic melanoma by Yervoy et al.,  2011.It is believed that protein-based 
therapy will become the treatment modality of choice for numerous diseases for next 10-20 
years  (Carter, 2011).  
Protein-based therapeutics is developing to be one of the largest class of new chemical 
entities in the drug industry (Gerngross, 2004). In European Union (EU) and the USA have 
approved about 100 genuine unmodified therapeutic proteins have been approved, for 
clinical purpose by July 2011 (Dimitrov, 2012). A large number of popular drugs are 
protein-based , conjuring more than 60 billion USD in sales annually (Dimitrov, 2012).  
In earlier applications, most of the therapeutic proteins were derived from natural resources, 
and their production is impeded by complicated and costly manufacturing procedures (Lu et 
al., 2006). The next generation of protein-based drugs were largely restricted to extracellular 
targets, or by targeting the receptors to transduce signals indirectly to cellular effectors 
(Gerngross, 2004). The size and electrical charges of these therapeutic proteins would 
prevent them from passing through the plasma membrane and directly interact with 
intracellular targets. However, there are more than 1,500 potential targets for disease 
treatment inside the cells without a clear specific receptor pathway to modulate their 
activities. The need for intracellular delivery and targeting to select host cell compartments 
represents a formidable hurdle to the development of prospective  protein-based biologics 
(Pisal et al., 2010). The various delivery methods currently used or being actively developed 
are further described in the following. 
 1.2. Delivery systems for therapeutic protein and peptides 
In the past 20 years, there has been a dramatic increase in the development of new large 
therapeutic molecules such as proteins, peptides and nucleic acids, aided by advances in 
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recombinant DNA technology and solid-phase synthesis. However, the safety and efficiency 
of these initial generations of therapeutic proteins were limited by high molecular weight, 
short half-lives, instability, immunogenicity, poor oral bioavailability, and poor penetration 
across biological membrane (Lu et al., 2006; Pisal et al., 2010). In the next generation of 
therapeutic proteins, there was a focus on either a change in the bioactive agent itself or by 
an improvement in drug formulation. The common concerns in developing therapeutic 
proteins include maintaining the delivery efficiency in different and challenging cells, 
ensuring rapid endosomal release, the ability to reach the target, drug activity at low doses, 
reducing cellular toxicity and improving facilities for therapeutic application (Heitz et al., 
2009). For example, early therapeutic proteins may be taken up into cells by endocytosis and 
gets degraded in the lysosomes, rather than being released into the cytoplasm where their 
targets are present. New approaches for drug formulation like liposomes-encapsulated 
proteins, cell-penetrating peptides, single-protein-core nanocapsules and thin polymer shell  
are now being employed (Lu et al., 2006; Yan et al., 2010; Carter, 2011).  
1.2.1. Liposome-encapsulated proteins 
The basic function of a cell membrane is to separate the cytoplasm from the extracellular 
environment, which also keep naked hydrophillic therapeutic proteins away from their 
intended intracellular targets. Liposomes are useful in drug-delivery because of their 
suitability in living bodies and adaptability to various types of drugs (Kaneda 2000; Hirai et 
al., 2015). A liposome-encapsulated protein is protected from pretease-mediated that results 
in improved delivery. The major reasons behind low efficiency in cargo delivery to target 
tissues by liposomes are the formation of aggregates with negatively-charged serum proteins, 
decreased macrophage uptake and insufficient drug entrapment (Kaneda, 2000; Mufamadi et 
al., 2011).   
1.2.2. Cell-penetrating peptides 
Large therapeutic biomolecules such as plasmid DNA, oligonucleotides, siRNAs, peptide-
nucleic acids (PNA), proteins, and peptides may not pass through the cell membrane readily. 
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This problem can be overcome with the conjugation of protein transduction domain (PTDs) 
also referred to as cell-penetrating peptides (CPPs) to the biomolecules (Heitz et al., 2009). 
In 1988, Frankel and Pabo discovered that the transactivator of transcription (TAT) protein 
of HIV can cross cell membranes and be efficiently internalized by cells, resulting in the 
transactivation of viral promoter in vitro. Most CPPs are short peptides composed 30-40 
amino acid residues. CPP-conjugated molecules readily cross the plasma membrane, in 
energy-dependent and/or independent mechanism and without the necessity of chiral 
recognition by specific receptors. Based on their origin, CPPs can be classified either as 
peptides derived directly from proteins, chimeric peptides formed by the fusion of two 
natural sequences, and synthetic CPPs rationally designed based on structure activity studies 
(Francesca Milletti, 2012).  
Nonetheless, CPPs may lack selectivity and CPP-conjugated proteins can be delivered into 
non-target cells as well, thereby increasing the risk of drug-induced toxic effect in normal 
tissues. In addition, there is a risk of proteolytic cleavage of CPPs in blood, thus reducing the 
therapeutic effect of the molecules that actually reach their targets in vivo (Koren and 
Torchilin, 2012; Bechara and Sagan, 2013).     
The current research on CPPs is focussed on three areas: (i) their use as a vector to transport 
various macromolecules for targeted cellular therapies in vitro and in vivo; (ii) to define the 
structural basis of the internalization capacities in order to engineer new CPP with optimum 
activity; (iii) to clarify the mechanisms of cell entry and final localization (Heitz at al., 2009; 
Bechara and Sagan, 2013; Copolovici et al., 2014).    
1.2.3. Nanocapsules composed of single-protein core and thin polymer shell  
Recent developments suggest that nanocapsules composed of single-protein core and thin 
polymer shell may be efficient means of delivery for therapeutic proteins. The single-protein 
core nanocapsules have been shown to be effective and low-toxicity intracellular protein 
delivery system. Moreover, nanocapsules conjugated with a protein core and a thin 
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permeable polymeric shell is able to remain stable at different pHs. However, this 
technology is still at the early experimental stages(Yan et al., 2010).     
1.3. Exosome-like nanovesicles as novel delivery vehicles 
Drug delivery system is under constant improvement to overcome the limitations of 
biological therapeutics, most notably the susceptibility to degradation, inability to cross 
biological membranes and eliciting immune responses. Extracellular vesicles (EVs) is a 
promising strategy being actively explored to deliver biological therapeutics to the cytosol of 
target cells (Kooijmans et al., 2012). James Rothman, Randy Schekman and Thomas Südhof 
shared the Nobel Prize in Physiology or Medicine 2013 for their work on the machineries 
regulating vesicle traffic, as one of the fundamental processes in cell physiology (Admin, 
2015). Their work laid down the groundwork on how vesicles are delivered with timing and 
precision intra- and extracellularly.   
Exosomes were first described in maturing sheep reticulocytes, involved in the 
externalisation of a receptor (Pan and Johnstone, 1983). Exosomes are 40-120 nm in 
diameter that are secreted by dendritic cells (DC), B cells, T cells, mast cells, epithelial cells 
and tumour cells. Exosomes are composed of lipids (Ramachandran and Palanisamy, 2012), 
proteins (Bellingham et al., 2012; Gonda et al., 2013) and nucleic acids (El Andaloussi et al., 
2013). Exosomes  are cup-shaped or  round well-delimited vesicles when observed under 
transmission and cryo-electron microscopy (Simons and Raposo, 2009; Orozco and Lewis 
2010; Lakhal and Wood, 2011; Bellingham et al., 2012). The density of exosomes range 
between 1.13 and 1.19 g/mL, and can be separated from multivesicular late endosomes by 
using sucrose-density gradient centrifugation (Simons and Raposo, 2009).   
Exosomes are produced from endocytic/exocytic pathways. Early endosome is formed from 
endocytic vesicles during cell membrane invagination. The inward budding of the endosomal 
membrane then forms intraluminal vesicles within the late endosomal compartments, which 
are also known as the Multivesicular Bodies (MVBs). The intraluminal vesicles are the 
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exosomes that are released into the extracellular space upon fusion of MVBs with the plasma 
membrane. Ceramides and phosphatidic acid are reported to be involved in inducing 
exosome formation and subsequent release. Proteins involved in gene silencing, Ago2 and 
GW182 associate with MVB, and are thought to facilitate the packaging of microRNAs in 
exosomes (Figure 1.1) (Marsh and van Meer, 2008; Laulagnier et al., 2004; Trajkovic et al., 
2008). Exosomes is believed to be a unique method of cell-to-cell communication. 
Exosomes affect the neighbouring cells through intercellular transfer of mRNA, microRNA, 
receptors and enzymes and are found to play important roles in immune dysregulation 
(O’Loughlin et al., 2012; El Andaloussi et al., 2013). The advantage of exosomes as 
mediator in extracellular communication is that they can be targeted to multiple locations. 
Exosomes have been shown to be promising as natural vehicles for the delivery of 
macromolecules. Wood and colleagues published a proof-of-concept study for the delivery 
of exogeneous siRNA using exosomes. Five other independent studies confirmed the 
potential of membrane vesicles in RNA transportation (Alvarez-Erviti et al., 2011).  
At the same time, exosomes are also investigated in their value as molecular diagnostic 
markers. Exosomes from tumour cells are found to express specific antigens which are 
enriched in heat shock proteins and activate antigen-presenting cell through delivery of 
danger signals (Sadallah et al., 2011). In addition, the surface markers on exosomes and their 
internal cargo are often reflective of the physiological status of the cells and organs. For 
example, exosomes found in urine may be developed as HIV and hepatitis C virus diagnostic 
tools as virus transmission has been shown to be facilitated through exosomes 
(Ramachandran and Palanisamy, 2012).    
The exact mechanism by which macromolecules are packaged into exosomes is not known. 
Thus extrapolating knowledge obtained from in vitro models to the more directly applicable 
area of translation research is a major focus of future research in exosomes (Ramachandran 
and Palanisamy, 2012). 
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Figure 1.1. Schematic representation of exosome production. Exosomes are intraluminal 
vesicles of endosomal origin. Recruitment of stimulating factors induces exosome formation, 
and the packaging of macromolecules. Exosomes are then released extracellularly when the 
multivesicular body (MVB) fused with plasma membrane. Figure is adapted from Lakhal 
and Wood, 2011. 
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1.4. Bicistronic expression vector  
Although less conventional, two or more exogenous genes could be expressed 
simultaneously in host cells by using a single plasmid under single promoter. Several 
strategies have been used such as fusing promoters to each open reading frame (ORF),or 
inserting splicing signals, proteolytic cleavage sites, Internal Ribosome Entry Site (IRES), or 
P2A peptides between two genes(Ghattas et al., 1991; Mizuguchi et al., 2000; Hellen and 
Sarnow, 2001).  
1.4.1. Internal ribosome entry site (IRES)  
Canonical translation initiation is dependent on ribosome scanning from the 5’-capped end 
of a mature eukaryotic mRNA to the initiator AUG codon (Borman et al., 1997). However, 
Pelletier and Sonenberg (1998) described an IRES element in 1988 which allows translation 
initiation by cap-independent manner in 5’ non-coding region of poliovirus RNA (Figure 
1.2). IRES sequence can be found in the RNA of all family members of Picornaviridae. The 
IRES DNA sequence is 450-500 nucleotides long and allows the expression of multiple 
genes on one mRNA. IRES DNA sequence can be inserted in between two genes for the co-
expression of both exogenous proteins under a single promoter (Jang et al., 1989; Ghattas et 
al., 1991; Mountford and Smith 1995). 
The IRES elements from picornaviruses can be classified into three distinct groups based on 
their activities under different salt conditions and the requirement of other co-factors. Type I 
IRES element is found in enterovirus and rhinovirus, while Type II IRES element is 
identified in the genome of cardiovirus and aphthovirus. Lastly, Type III IRES element is 
found in hepatitis virus (Liebig et al., 1993; Borman et al., 1995; Borman et al., 1997) 
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Figure 1.2. IRES-mediated translation- bicsictronic constructs for the heterlogous co-
expression of two hypothetical proteins. IRES sequence is inserted between the coding 
sequences of protein 1 and protein 2 to drive a cap-independent, internal initiation of protein 
2 translations, in parallel to Protein 1 cap-dependent translation initiated at the bicistron 
transcript 5’ end.  
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1.4.2. Foot-and-mouth disease virus (FMDV)-2A peptide 
Ryan and colleagues  first identified a “self cleaving” peptide at the 2A region of foot-and-
mouth disease virus (FMDV). This observation is subsequently observed in all other 
members of Picornaviridae that have a conserved peptide sequence of around 18-22 amino 
acids. For example, the P2A peptide sequence is A T N F S L L K Q A G D V E E N P G P, 
and the “cleavage” occurs between the Glycine and Proline residues at the C-terminus of the 
P2A peptide. These 2A-like CHYSEL (cis-acting hydrolase elements) peptide sequences 
lead to ribosome “skipping” during translation whereby the single peptide bond in between 
Glycine and Proline is not synthesised. The 2A peptide-mediated cleaving property is 
subsequently used in co-expression of exogenous proteins in cell lines, embryonic stem cells 
and neurons (Lengler et al,. 2005; Kim et al., 2011) shown at Figure 1.3.   
A functional model of 2A-mediated “cleavage” strategy was proposed as such: (i) Ribosome 
initiates translation at the start codon of the ORF upstream of 2A peptide sequence; (ii) 
elongation of peptide continues until the C-terminus of FMDV 2A sequence; (iii) the nascent 
peptide chain is released at a C-terminus of the FMDV 2A sequence; (iv) the ribosome 
subsequently re-initiate translation of downstream sequences and terminates normally at the 
stop codon of the entire ORF (Brown and Ryan, 2010).  
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Figure 1.3. 2A peptide-mediated translation - bicsictronic constructs for the 
heterlogous co-expression of two hypothetical proteins. 2A sequence is inserted between 
the coding sequences of protein 1 and protein 2 to induce ‘ribosomal skipping’ during 
translation leading to the co-translational release of the two proteins.  
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1.5. Literature review for model protein 
Previous studies suggested that exosomes formation can be induced by overexpression of 
certain virus proteins such as HIV-1 Nef protein (Ali et al., 2010; Shelton et al., 2012; 
Campbell et al., 2012), Viral infectivity factor (Vif) (Columba and Federico 2013), and 
Vesicular Stomatitis Virus - G protein (VSV-G) (Mangeot et al., 2011) . 
1.5.1. HIV-1 Nef protein 
Human immunodeficiency virus type-1 (HIV-1) accessory protein Nef is 27 kDa in size and 
is produced early during HIV infection of cells. Nef protein plays a major role in the 
pathogenesis of HIV and simian immunodeficiency virus (SIV) infections (S. Y. Kim et al., 
1989). It affects viral infectivity and the down-regulation of cell surface CD4 on T cells 
through interaction with host cell plasma membrane and proteins (Sanfridson et al., 1997). 
Most of the studies are focused on intracellular functions of Nef in infected cells. However, 
Nef protein is also secreted from Nef-transfected and HIV-1 infected cells, and can be 
detected in the serum of clinical samples from AIDS patients. Protein markers for 
endosomes or lysosomes, such ascathepsin D and LAMP2 are present in Nef-induced 
intracellular vesicles, indicating the origin of these vesicles. This is in line with the 
observation where expression of Nef induces the intracellular accumulation of MVBs 
(Sanfridson et al.,1997; Stumptner-Cuvelette et al., 2003). These Nef-induced exosome-like 
vesicles were also found to contain acetylcholinesterase (AChE) and CD45 (Ali et al., 2010). 
Thus, AchE and CD45 can be used as specific markers to detect Nef-induced exosome-like 
vesicles. The secreted exosomal Nef protein could be important for the HIV-1 pathogenesis 
by modulating the behaviour of  non-infected neighbouring cells and inducing apoptosis in 
other non-infected CD4
+
 T cells (Campbell et al., 2008; Shelton et al., 2012).     
1.5.2. HIV-1 Vif protein 
Human immunodeficiency virus type-1 (HIV-1) protein, virion infectivity factor (Vif) is a 23 
kDa cytoplasmic protein. Vif is expressed from one of the accessory genes during the late 
phase of HIV-1 replication. There are several known regulatory roles of Vif, including the 
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modulation of proviral DNA synthesis, viral core structure in released virions, and the 
efficient incorporation of envelop protein into release virion. In addition, Vif protein is 
secreted in small exosome-like vesicles , which is detected using RT-PCR method (Navid 
Madani and David Kabat, 1998; Hui Zhang et al., 1998; Columba Cabezas and Federico, 
2013). As such, Vif is chosen as one of the proteins to be tested regarding the role in 
exosome formation.  
1.5.3. Vesicular stomatitis virus - G protein (VSV-G) 
Vesicular stomatitis virus (VSV) is a type of rhabdovirus first characterized in 1982 
(Lefrancois and Lyles, 1982). The G protein of VSV (VSV-G) is found on the cell surface of 
the infected host cells and is important for the direct budding of virus from the plasma 
membrane. VSV-G is synthesized on membrane bound polyribosomes (Rose and Gallione,  
1981).  The presence of VSV-G can increase the stability of vector particles during 
purification process (Burns et al., 1993). In a recent study, Mangeot and colleagues reported 
a novel method using VSV-G induced vesicles (named as gesicles) as a tool to deliver 
proteins in human cells. The expression of VSV-G is sufficient to induce the budding of 
pseudovirion, transmitting the replicons to neighbour cells. Therefore, we also tested VSV-G 
on its ability to induce exosomes when co-expressed in bicistronic transfection vector. 
1.6. Aim of this study 
Previous study has shown that the N-terminal portion (amino acid 1-70) of HIV-1 Nef 
protein is sufficient to induced exosome secretion when expressed in a variety of cells such 
as THP1 monocytes, Jurkat T cells and HEK 293 (Ali et al., 2010; Campbell et al., 2012; 
Shelton et al., 2012). We have named it exosome-inducing peptide (ExIP). Interestingly, the 
exosomes secreted from induce exosome secrrtion expressing cells contained exosomes and 
its mRNA, and also proteins and RNA from the host cell (US Patent 20100317566). This 
indicates that the exosomes can package proteins and mRNA from the cytoplasm. Following 
up on that, we are interested in examining the efficiency of various other viral proteins in 
inducing exosomes formation and the potential for use in packaging therapeutic proteins. A 
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bicistronic vector model will be used for simultaneous expression of GFP and different 
proteins of viral origin (Nef, Vif, and VSV-G) in 293-T cells. Various bicistronic vectors 
using internal ribosomal entry site (IRES) and 2A peptide (from FMD virus) will be tested. 
From this, we aim to complete a proof-of-concept study to show that recombinant protein 
(GFP) can be packaged and released in induced exosomes (Figure 1.4). This study will serve 
as a platform for further research in developing a novel exosome-based autologous 
production, packaging, and delivery system of recombinant therapeutics to target cells. Since 
exosomes are naturally produced by a variety of cell types, they do not elicit immune 
response thus are promising vehicles to deliver biologically active macromolecules.  
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Figure 1.4. Pathway of recombinant proteins packaging and release in Nef-induced 
exosome.  
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1.6. Main goal of the research 
Exosomes are nano-sized membranous vesicles, produced naturally by cells as a means of 
cell-to cell communication. We aim to engineer cells to produce therapeutic protein-
containing exosomes. The main goal of this work is to construct novel mammalian 
expression vectors that can simultaneously induce exosome production and packaging of 
recombinant protein into produced vesicles. 
1.6.1. Specific objectives: 
1. To construct bicistronic vectors for simultaneous expression of exosome-inducing 
protein(s) and GFP (a model protein). 
2. To evaluate various viruses -derived ExIPs (Nef, Vif, and VSV-G) for their ability to 
induce exosome biogenesis. 
3. To demonstrate that the released exosome contain GFP.  
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CHAPTER 2. MATERIAL AND METHODS 
2.1. Materials 
2.1.1. Culture media 
See Appendix A for culture media used in this study (refer to page 148). 
2.1.2. General buffers, stock solutions, and antibiotics 
See Appendix A for general buffers, stock solutions, and antibiotic used in this study (refer 
to page 150).  
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2.2. Experimental strategy 
PCR amplification was used to propagate the gene sequences used for the construction of 
various encoding plasmid vectors. Nef1-70 (1-70 amino acid of HIV-1 Nef protein), nef206 
(encoding HIV-1 Nef full length protein), gfpNS (encoding GFP but without stop codon) and 
gfp (encoding full length green fluorescent protein) were PCR amplified from pQBI-Nef1-
70GFP (Ali et al. 2010; Shelton et al., 2012). The vif gene was PCR amplified from pNL4.3 
plasmid. The VSV-G gene was PCR amplified from pCMV-VSV-G plasmid. For cloning 
purpose, the genes were PCR amplified using either KAPA Hifi DNA polymerase (KAPA 
Biosystem) or Pfu DNA polymerase (Thermo Scientific, #EP0571). The number of PCR 
amplification cycles was kept below 25 to minimize the chances of PCR-mediated mutations. 
PCR-amplified DNA was resolved on either 0.7% (vector) or 1.5% (insert) agarose gel  
using TAE as running buffer and then purified using PCR Clean-up kit (Macherey-Nagel, 
#740609). The purified DNA (insert or vector) was treated with restriction enzymes for 
optimal time and temperature. The linearised vector DNA was further dephosphorylated 
using 1 µL of shrimp alkaline phosphatase (rSAP, New England BioLabs (NEB)) at 37°C for 
1 hour to prevent self-ligation. The restricted insert and vector DNA were purified using 
NucleoSpin® Gel and PCR Clean-up kit (Macherey-Nagel, #740609). Then the DNA 
concentration was quantified using Qubit® dsDNA HS Assay Kit (Life technologies 
Q32851). The vector and insert DNA were mixed in 1:3 ratios and ligated using 1µL of T4 
ligase (NEB). The ligation mixture was incubated at 16°C for 8-12 hours. 
The parent vector pEF1α-IRES contained beta lactamase (bla) gene for the selection of 
positively transformed bacterial colonies on LB agar plate containing 100 µg/mL Ampicillin. 
Ligation products were transformed into DH5α competent cells by heat shock. The DH5α 
cells were spread on LB agar plates containing 100 μg/mL Ampicillin and incubated at 30°C 
overnight (16-18 hours). Ten positively-transformed bacterial colonies were selected for 
colony PCR to verify the presence of correct insert. The vector and insert-specific primer 
were used for colony PCR. The bacterial colonies positive for expected amplicon were 
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grown in LB broth containing Amplicillin at 30°C overnight. The plasmid was isolated using 
NucleoSpin
®
 Plasmid Extraction Kit (Macherey-Nagel, #740588.250) and verified by 
appropriate restriction enzymes. Upon verification, the DH5α cells transformed with desired 
plasmid were grown in 100 mL of LB broth containing Amplicillin at 30°C overnight. The 
expression plasmid was purified using Endotoxin-free Plasmid Extraction Kit (Macherey-
Nagel, #740420). The expression plasmid was concentrated using phenol chloroform 
extraction and ethanol precipitation, adjusted to 1 µg/µL in dH2O and stored at -20°C.   
Endotoxin-free plasmid was transient transfect into HEK293 or 293T cells. The supernatant 
(which contained exosome) was collected at 24 hours and 72 hours. The transfected cells 
were harvested at 72 hours to analyze transcription or replication of the transfected gene. The 
culture medium was collected and centrifuged by differential ultracentrifugation to isolate 
and purify the exosome.  
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Figure 2.1. Experimental overview of this study 
PCR amplification of 
nef1-70 and gfp genes 
Clone nef1-70 and gfp 
genes into pEF1α-
IRES vector 
pEF1α-Nef1-70-
IRES-GFP bicistronic 
vector vector 
pEF1α-GFP-IRES-
Nef1-70 bicistronic 
vector vector 
Replace IRES with 
p2A peptide 
pEF1α-GFP-p2A-
Nef1-70 vector  
pEF1α-GFP-p2A-
Nef206 vector 
 pEF1α-GFP-p2A-Vif 
vector  
 pEF1α-GFP-p2A-
VSVG vector  
 pEF1α-GFP-p2A-Vif 
-6His vector  
pEF1α-GFP-p2A-
VSVG-6His vector  
Purify all plasmids by 
MIDI preps 
Transfect into 
HEK293 and 293T 
cells and collect 
supernatent 
Harvest exosomes by 
ultracentrifugation  
SDS-PAGE / Western 
Blot analysis  
21 
 
2.3. Methods 
2.3.1. Bacterial strains and culture conditions 
The DH5α E.coli (NEB, #C2987H) strain was used to transform plasmid vectors. E.coli was 
maintained on Luria Bertani (LB) agar or broth without any antibiotic. The competent E.coli 
DH5α were prepared as follows: 
2.3.1.1. Preparation of competent cells 
First, 0.5 M piperazine-1,2-bis[2-ethanesulfonic acid] (PIPES) was prepared by adding 15.1 
g of PIPES in 80 mL of ddH2O water. Then, the pH was adjusted to pH 6.7 using 5M KOH. 
The volume was made to 100 mL using ddH2O water. The buffer was sterilized using 
syringe filters (0.45 µm, Sartorius Stedim Minisart® Syringe Filters). PIPES buffer was 
aliquoted in 20 mL and stored at -35°C. The inoue transformation buffer was prepared by 
mixing the following chemicals: 10.88 g of MnCl2.4H2O, 2.2 g of CaCl2.2H2O, 18.65 g of 
KCL and 20 mL of PIPES (0.5 M, pH 6.7) in 800 mL of ddH2O water. The final volume was 
adjusted to 1 L with ddH2O water. The Inoue transformation buffer was filter sterilized using 
0.45 µm and stored in 50 mL aliquots at -80 °C.  
A single colony of DH5α bacterial was used initiate to a starter culture in 10 mL of SOB 
medium in a 100 mL Schott bottle. The culture was incubating for 8 hours at 37°C while 
shaking at 250 rpm. The starter culture was then transferred into three separate 1 L flasks, 
each containing 100 mL of SOB medium. The first flask received 4 mL of starter culture, the 
second flask received 1.6 mL and the third flask received 0.8 mL. Those flasks were 
incubated at room temperature (22°C - 25°C) with moderate shaking (80 rpm) overnight. 
The optical density culture in three flasks was at 600 nm by using spectrophotometer. The 
culture with 0.4-0.5 OD600 was transferred to an ice-water bath and incubated for 10 minutes. 
The other two cultures were discarded. The bacterial cells were harvested by centrifugation 
at 2500X g for 15 minutes at 4°C. The SOB medium was decanted and the pellet was dried 
for 5 minutes by inverting the tubes on a tissue paper. The cells were gently resuspended in 
32 mL of ice-cold Inoue transformation buffer and centrifuged at 2,500X g for 15 minutes at 
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4°C. The supernatant was removed completely using vacuum aspirator. Then, 8 mL of ice-
cold Inoue transformation buffer was used to resuspend the cells gently. Then, 0.6 mL of 
DMSO was added and mixed by swirling. The cells were than incubated in wet ice for 10 
minutes. The cells were the added into autoclaved and UV-sterilized 0.5 mL pre-chilled 
microcentrifuge tubes. Three hundred microlitter competent cells were frozen in liquid 
nitrogen and stored at -80°C. 
 2.3.1.2. Short-term storage of bacterial strains 
Sixteen to eighteen hour old agar plates were wrapped with parafilm to prevent dehydration 
and contamination and stored at 4°C for up to 1 month.   
To recover the E.coli, bacteria colonies were inoculated in 2-5 mL LB broth (with or without 
selection antibiotic). Bacteria were then cultured at 30°C for 12-16 hours with shaking (250 
rpm).  
2.3.1.3 Long-term storage of bacterial strains 
For storage, 1 mL of 8-12 hours old bacteria culture was added into 500 µL of LB broth / 60% 
glycerol. The total culture was split into two 1.5 mL micro-centrifuge tubes and stored at       
-80°C for up to 1 year.   
For recovery, the bacterial glycerol stock was placed on wet ice immediately after removal 
from -80°C freezer. A sterile wire loop was used to transfer frozen chips from the glycerol 
stock and spread on a LB agar plate (with or without selection antibiotics). The agar plate 
was then incubated at 30°C for 18 hours until colonies were visible.   
2.3.2. Primer Design  
All oligonucleotides were obtained from Integrated DNA Technologies (IDT). Primers were 
designed using the Vector NTI Advance® Sequence Analysis software. The lyophilised 
oligonucleotides were dossolved in Tris - HCl (pH 8.0, 10 mM) to a final concentration of 10 
µM. working stock were prepared by adding 100 µM stock to 10 µM stock.  
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Several factors were considered during primer design. Primers lengths were kept within 18-
30 nucleotides long. The melting temperatures (Tm) of forward and reverse primers were 
adjusted to within 5°C of each other. The GC contents of the primer were kept between 40-
60%. Besides that, the 3’- ends of primers were preferentially C or G to avoid formation of 
secondary intermolecular structures that affect the amplification step during PCR (Frey et al. 
2008). Three to four nucleotides were also added 5’ to the restriction site as that would 
increase the restriction enzyme efficiency. Finally, extra care was taken to avoid intra-primer 
homology or inter-primer that could lead to self-dimers and primer-dimers.  
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Table 2.1. Oligonucleotides for plasmid construction 
Primer Name Sequence (5’        3’) Tm (°C) 
Nef1-70-NheI-F TGACGCTAGCATGGGTGGCAAGTGGTCAA 60.7 
Nef1-70-MluI-R GCGCACGCGTTCAATGGTGATGGTGGTGATGAGCTGCGACTG
GAAAACCCACCTCTTC 
58.5 
GFP-XbaI-F GTCCTCTAGAATGGCAAGCAAAGGAGAAGAACTCTTCAC 56.9 
GFP-NotI-R GGAAGCGGCCGCTCAGTTGTACAGTTCATCCATGC 52.2 
GFP-NheI-F GTCCGCTAGCATGGCAAGCAAAGGAGAAGAACTCTTCAC 56.9 
GFP-MluI-R GGAAACGCGTTCAGTTGTACAGTTCATCCATGC 52.2 
Nef1-70-XbaI-F TGACTCTAGAATGGGTGGCAAGTGGTCAA 60.7 
Nef1-70-NotI-R GCGCGCGGCCGCTCAATGGTGATGGTGGTGATGAGCTGCGAC
TGGAAAACCCACCTCTTC 
58.4 
GFP-NheI-F TAGGCTAGCATGGCAAGCAAAGGAGAAGAAC 54.2 
GFPNS-MluI-R ACCACGCGTGTTGTACAGTTCATCCATGCCATG 55.8 
Nef1-70-XbaI-F TGACTCTAGAATGGGTGGCAAGTGGTCAA 60.7 
Nef206-NotI-R GGAAGCGGCCGCTCAGTGATGGTGATGGTGATGAGCTGCG
CAGTTCTTGAAGTACTCCGG 
50.8 
P2A-F CGCGTGGTAGTGGTGCTACTAATTTTTCTCTTCTTAAACA
AGCTGGTGATGTTGAAGAAAATCCTGGTCCTT 
- 
P2A-R CTAGAAGGACCAGGATTTTCTTCAACATCACCAGCTTGTT
TAAGAAGAGAAAAATTAGTAGCACCACTACCA 
- 
MluI-P2A-F CACGCGTGGTAGTGGTGCTAC 55.5 
pEF1-R GCATTAACCCTCACTAAAGGG 50 
